Subscribe to our newsletter
Menu
CorEvitas is now enrolling qualified sites for the GPP Registry. If you are interested in participating, please get in touch using the link below.
Generalized Pustular Psoriasis (GPP) is a rare disease affecting an estimated one out of every 10,000 people in the U.S., with most studies showing it affects more women than men. It is characterized by the sudden widespread eruption of rash and sterile pustules, with or without systemic inflammation, recurring from once a year to more than three times a year. These flares are often accompanied by severe complications which, if left untreated, can be life threatening.
This registry prospectively collect detailed patient-level data enabling assessment of the natural history of the disease and treatment patterns, along with the prevalence and incidence of comorbidities in patients with the disease.
Granular, longitudinal outcome measures will be collected during registry visits, some of which include clinician-reported GPP outcomes, lab measures and treatment history, as well as patient-reported outcomes assessing symptom impact and quality of life. Drug safety data also will be collected, including serious adverse events and other adverse events of special interest.
Read the Press Release, here.
Dean for Clinical Therapeutics, Icahn School of Medicine at Mount Sinai | Professor and Chairman Emeritus of the Kimberly and Eric J. Waldman Department of Dermatology at Mount Sinai | Past president, American Academy of Dermatology | Chairman emeritus, Medical Board of the National Psoriasis Foundation
Clinical Professor, Department of Dermatology, Yale University | Clinician, Central Connecticut Dermatology | Vice President/President-Elect, International Psoriasis Council | Editor in Chief of the Journal of Psoriasis and Psoriatic Arthritis | Former Chair of Dermatology at the University of Connecticut Health Center
